Home Topics Drug Discovery Efficient Identification and Management of Degradant Data in Process Development Eli Lilly will apply Dicerna Pharmaceuticals’ GalXC™ RNA interference (RNAi) technology platform to discover, develop, and commercialize new treatments based on more than 10 targets in cardio-metabolic disease, neurodegeneration, and pain, through a collaboration that could generate more than $3.7 billion for Dicerna. [© lily/Fotolia] Efficient Identification and Management of Degradant Data in Process Development April 4, 2019 ResourcesBig dataDiagnosisDiagnostic techniquesDrug development (Pharmacology)Drug discoveryDrug research and developmentDrugsMass spectrometryMedicine, Diagnosis, and TherapeuticsPharmacologySoftwareTechnology and Computational Biology
